ClinicalTrials.gg
Not yet recruitingNCT07049120Updated Jul 3, 2025

Post-Market Study of ZENFLEX Pro Stent for Femoropopliteal Artery Lesions

An interventional study of ZENFLEX Pro™ Peripheral Drug-eluting Stent System in Peripheral Arterial Disease, sponsored by Zhejiang Zylox Medical Device Co., Ltd.. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Zhejiang Zylox Medical Device Co., Ltd. · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
153
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Peripheral Arterial Disease with a site in Poland — 7 open to participants now, 9 under way, 3 of them phase 3. Peripheral Arterial Disease · Poland.

Planned enrollment
15th of 28
153 · median 220
Started
2025
with 4 others
No phase
16 of 31
4 open now
Registered
28th of 31
by date

Among the 31 studies in Peripheral Arterial Disease with a site in Poland, this one is the 15th largest by planned enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 with no phase, and was the 28th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

7 of the 31 studies in Peripheral Arterial Disease with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Peripheral Arterial Disease with a site in Poland, or all of them as a file.
02

Study summary

This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion. A total of 153 subjects will be followed at 1, 6, and 12 months. The primary endpoint is primary patency at 12 months.

Read the detailed description

This is a prospective, multi-center, single-arm, post-market registry study designed to ensure continued evaluation of real-world safety, performance and efficacy of the ZENFLEX Pro™ Peripheral Drug-eluting Stent System in the treatment of femoropopliteal artery stenosis or occlusion. A total of 153 subjects will be enrolled in this study. Follow-up visits will be scheduled at 1-, 6-, and 12-months post-procedure. The primary endpoint is primary patency at 12 months. Secondary endpoints include technical success, procedural success, secondary patency rate, target lesion revascularization (TLR), clinically driven target lesion revascularization (CD-TLR), Rutherford classification, and ankle-brachial index (ABI). Safety endpoints include major adverse events, adverse events, all-cause mortality, major amputations, minor amputations, and stent fractures.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical Inclusion Criteria:

    1. Aged 18 to 80 years, regardless of gender.
    2. Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3, 4 or 5.
    3. Subject (or legal guardian, if applicable) is willing and able to provide consent before to the performance of any study-specific tests or procedures, has signed the consent form and agrees to attend all required follow-up visits.
  • Angiographic Inclusion Criteria:

    1. Stenotic, restenotic or occlusive lesion(s) located in the native superficial femoral artery (SFA) and/or proximal popliteal artery (PPA) (i.e., within the P1 segment):

      1. Degree of stenosis ≥70% by visual angiographic assessment.
      2. Vessel diameter ≥4.0 mm and ≤6.5 mm.
      3. Total lesion length (or series of lesions) ≥ 10 mm and ≤ 140 mm (Note: Lesion segment(s) must be fully covered with one stent).
      4. Chronic total occlusion with a total lesion length of ≤120 mm.
    2. Patent popliteal and infrapopliteal arteries, with single-vessel runoff or better, defined as at least one of the three vessels remaining patent (i.e., \<50% stenosis) down to the ankle or foot.

Exclusion criteria

Exclusion Criteria:

  • Clinical exclusion criteria:

    1. Pregnant or breastfeeding women, or women/men planning to conceive.
    2. Subjects who have had or are planned for major amputation (at or above the ankle level).
    3. Subjects known to be allergic or intolerant to materials used in the device or treatment drugs, including nitinol, paclitaxel, aspirin, clopidogrel, heparin, rivaroxaban, contrast agents, etc.
    4. Subjects with serum creatinine ≥2.5 mg/dL or currently undergoing dialysis.
    5. Subjects with known, uncorrectable hemorrhagic disorders or severe coagulation dysfunction ( (PT) or activated partial thromboplastin time (aPTT) ≥2 times the , or count \<80×10⁹/L).
    6. Previously stented target lesion/vessel.
    7. Target lesion/vessel previously treated with drug-coated balloon \<12 months prior to enrollment.
    8. Subjects with a of less than 1 year.
    9. Subjects who have received local or systemic thrombolysis treatment within 48 hours prior to enrollment.
    10. Subjects diagnosed with major clinical diseases or unstable conditions within the past 3 months, such as severe heart failure, unstable angina, myocardial infarction, or stroke, severe neurological or psychiatric history, severe infections, gastrointestinal bleeding, or active disseminated intravascular coagulation.
    11. Subjects currently participating in another clinical trial involving drugs or medical devices.
    12. Subjects whom the investigator considers unsuitable for participation in the clinical trial.
  • Angiographic exclusion criteria:

    1. Presence of aneurysm in the target vessel.
    2. Heavily calcified lesions (Peripheral Arterial Calcium Scoring System [PACSS] grades 3-4).
    3. The target lesion requires the use of plaque excision, laser, or other debulking devices that may damage the vessel intima.
    4. The guidewire cannot pass through the target lesion, or percutaneous transluminal angioplasty (PTA) balloon cannot be used for pre-dilation.
    5. Acute ischemia and/or acute thrombosis of the SFA/PPA prior to enrollment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
153 participants (estimated)

Study arms

  • Experimental
    ZENFLEX Pro

    Subjects in this arm will receive treatment with the ZENFLEX Pro™ Peripheral Drug-eluting Stent System for femoropopliteal artery stenosis or occlusion. The procedure will be performed according to the device's instructions for use (IFU). Follow-up assessments will be conducted at 1, 6, and 12 months post-procedure to evaluate safety, efficacy, and performance outcomes.

    Device: ZENFLEX Pro™ Peripheral Drug-eluting Stent System

Interventions

  • DeviceZENFLEX Pro™ Peripheral Drug-eluting Stent System

    The ZENFLEX Pro™ Peripheral Drug-eluting Stent System will be implanted in patients with femoropopliteal artery lesions to evaluate safety and efficacy outcomes. The device is designed to provide mechanical support and deliver antiproliferative drug locally to reduce restenosis. The procedure will be performed via standard endovascular techniques.

06

What researchers measure

Primary outcomes

  1. Number of Participants Reaching Primary Patency

    Primary patency is defined as a binary endpoint and will be determined to be a success when the duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤2.4 at the 12-month follow-up visit in the absence of clinically driven TLR or bypass of the target lesion.

    Time frame: 12 months post-procedure

Secondary outcomes

  1. Number of participants with successful stent delivery and deployment resulting in ≤30% residual stenosis

    Technical success is defined as the delivery and deployment of the assigned study stent to the target lesion to achieve residual angiographic stenosis no greater than 30% assessed visually.

    Time frame: During the procedure

  2. Number of participants with procedural success (technical success and no MAEs within 24 hours)

    Procedural success is defined as technical success with no major adverse events (MAEs) noted within 24 hours of the index procedure.

    Time frame: Within 24 hours post-procedure

  3. Number of participants with primary patency

    Primary patency is defined as a binary endpoint and will be determined to be a success when the duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤2.4 at the 12-month follow-up visit in the absence of clinically driven TLR or bypass of the target lesion.

    Time frame: 6 months post-procedure

  4. Number of participants with secondary patency

    Secondary patency at 6 months and 12 months. Secondary patency is defined as the absence of restenosis in the target lesion on DUS follow-up, with a diameter stenosis of ≤50% (PSVR ≤2.4), regardless of whether the target lesion has undergone reintervention.

    Time frame: 6 and 12 months post-procedure

  5. Number of participants undergoing target lesion revascularization (TLR)

    TLR is defined as any repeat revascularization (endovascular or surgical) of the target lesion due to restenosis or occlusion, regardless of symptoms or diagnostic findings.

    Time frame: At 1, 6, and 12 months post-procedure

  6. Clinically Driven Target Lesion Revascularization (CD-TLR)

    A target lesion revascularization will be considered clinically driven if it occurs within 5 mm proximal or distal to the original treatment segment with diameter stenosis ≥50% by quantitative angiography (QA) and the subject has recurrent symptoms (≥1 change in Rutherford Classification or associated with decreased ABI/TBI of ≥20% or ≥0.15 in the treated segment. TBI allowed in cases of incompressible vessels.)

    Time frame: At 1, 6, and 12 months post-procedure

  7. Change in Rutherford Classification at 1, 6, and 12 months

    Rutherford Peripheral Arterial Disease (PAD) Classification is a clinical grading system used to assess the severity of lower limb ischemia. The scale ranges from 0 to 6, where higher scores indicate more severe disease. Each category is defined by clinical symptoms and objective hemodynamic criteria as follows: 0: Asymptomatic - Normal treadmill or stress test 1. Mild claudication - Completes treadmill test; post-exercise ankle pressure (AP) \<50 mmHg, and \>25 mmHg drop from resting blood pressure 2. Moderate claudication - Symptoms between categories 1 and 3 3. Severe claudication - Cannot complete treadmill test; post-exercise AP \<50 mmHg 4. Ischemic rest pain - Resting AP \<40 mmHg, with flat or low-amplitude ankle/metatarsal pulse volume recording (PVR); toe pressure (TP) \<30 mmHg 5. Minor tissue loss - Non-healing ulcer or localized gangrene with edema; resting AP \<60 mmHg, ankle or metatarsal PVR flat or low amplitude; TP \<40 mmHg 6. Major tissue loss - Tissue loss extendi

    Time frame: 1, 6, and 12 months post-procedure

  8. Change in Ankle-Brachial Index (ABI) from baseline at 1, 6, and 12 months

    The ratio between the systolic pressure measured at the ankle and the systolic pressure measured in the arm as follows: Ankle: The systolic pressure will be measured in the target limb at the arteria dorsalis pedis and/or the arteria tibialis posterior. If both pressures are measured, the highest pressures will be used for the ABI calculation. Brachial: The systolic pressure will be measured in both arms, and the highest of both pressures will be used for the ABI calculation.

    Time frame: 1, 6, and 12 months post-procedure

07

Study locations

1 site
  • American Heart of Poland, Małopolskie Cardiovascular Center PAKS Chrzanów
    Chrzanów, Chrzanów 32-500, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for May 2027, 23 months later.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 23 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jul 3, 2025
StartEst.
Jun 30, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07049120
Lead sponsor
Zhejiang Zylox Medical Device Co., Ltd.
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Jun 30, 2025 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Jul 3, 2025

Study contacts

Przemysław Nowakowski
Contact
nowakowski.mcsn@gmail.com
+48 32 625 81 20
Tao Liu
study director · Zhejiang Zylox Medical Device Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion